Cognition and obstructive sleep apnea in Parkinson's disease: randomized controlled trial of positive airway pressure (COPE-PAP trial).

IF 5.6 2区医学 Q1 Medicine

Sleep Pub Date : 2025-02-13 DOI:10.1093/sleep/zsaf038

Annie C Lajoie, Anne-Louise Lafontaine, R John Kimoff, Andrea Benedetti, Ann R Robinson, Marie Létourneau, Joelle Crane, Amanda Scanga, Francine Noel, Marta Kaminska

{"title":"Cognition and obstructive sleep apnea in Parkinson's disease: randomized controlled trial of positive airway pressure (COPE-PAP trial).","authors":"Annie C Lajoie, Anne-Louise Lafontaine, R John Kimoff, Andrea Benedetti, Ann R Robinson, Marie Létourneau, Joelle Crane, Amanda Scanga, Francine Noel, Marta Kaminska","doi":"10.1093/sleep/zsaf038","DOIUrl":null,"url":null,"abstract":"Study objectives: This randomized controlled trial assessed the effects of positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) on cognition in patients with Parkinson's disease (PD).Methods: Individuals with PD with Montreal Cognitive Assessment (MoCA) < 27 and OSA were randomized to PAP or nasal dilator strips (placebo) for 6 months. The primary outcome was the change in MoCA from baseline to 6 months compared by t-test between groups by intention to treat (ITT). Sensitivity and per protocol (PP) analyses were performed, adjusting for potential confounders. Secondary outcomes included patient-reported and motor outcomes. Exploratory outcomes comprised detailed neurocognitive tests.Findings: We randomized 94 participants (31% female) with mean age 67.3 (SD 10.5) years, body mass index 28.1 (4·7) kg/m2 and MoCA 22.7 (3.5). The change in MoCA in the PAP group (n=48) was 0.60, 95%CI [-0.08, 1.29] and in the control group (n=46) -0.39, 95%CI [-1.21, 0.43]; between-group difference 1.00, 95%CI [-0.06, 2.05] (ITT). Adjusted ITT analyses showed improved MoCA by 1.44, 95%CI [0.09, 2.79], in treated vs. control groups. In PP analyses, the adjusted between-group difference was 1.43, 95%CI [0.054, 2.81] between PAP (n=33) vs. control (n=41) groups. Non-motor symptoms, depression and sleep quality scores, and performance on certain executive and psychomotor tasks improved with PAP. PP analyses also showed significant improvement in motor function in PAP compared to control groups.Conclusions: Evaluation for OSA in PD patients with reduced cognition should be considered as OSA treatment may improve cognitive function, and possibly patient-reported and motor outcomes.","PeriodicalId":22018,"journal":{"name":"Sleep","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sleep/zsaf038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Study objectives: This randomized controlled trial assessed the effects of positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) on cognition in patients with Parkinson's disease (PD).

Methods: Individuals with PD with Montreal Cognitive Assessment (MoCA) < 27 and OSA were randomized to PAP or nasal dilator strips (placebo) for 6 months. The primary outcome was the change in MoCA from baseline to 6 months compared by t-test between groups by intention to treat (ITT). Sensitivity and per protocol (PP) analyses were performed, adjusting for potential confounders. Secondary outcomes included patient-reported and motor outcomes. Exploratory outcomes comprised detailed neurocognitive tests.

Findings: We randomized 94 participants (31% female) with mean age 67.3 (SD 10.5) years, body mass index 28.1 (4·7) kg/m2 and MoCA 22.7 (3.5). The change in MoCA in the PAP group (n=48) was 0.60, 95%CI [-0.08, 1.29] and in the control group (n=46) -0.39, 95%CI [-1.21, 0.43]; between-group difference 1.00, 95%CI [-0.06, 2.05] (ITT). Adjusted ITT analyses showed improved MoCA by 1.44, 95%CI [0.09, 2.79], in treated vs. control groups. In PP analyses, the adjusted between-group difference was 1.43, 95%CI [0.054, 2.81] between PAP (n=33) vs. control (n=41) groups. Non-motor symptoms, depression and sleep quality scores, and performance on certain executive and psychomotor tasks improved with PAP. PP analyses also showed significant improvement in motor function in PAP compared to control groups.

Conclusions: Evaluation for OSA in PD patients with reduced cognition should be considered as OSA treatment may improve cognitive function, and possibly patient-reported and motor outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Sleep Medicine-Neurology (clinical)

CiteScore

8.70

自引率

10.70%

发文量

期刊介绍： SLEEP® publishes findings from studies conducted at any level of analysis, including: Genes Molecules Cells Physiology Neural systems and circuits Behavior and cognition Self-report SLEEP® publishes articles that use a wide variety of scientific approaches and address a broad range of topics. These may include, but are not limited to: Basic and neuroscience studies of sleep and circadian mechanisms In vitro and animal models of sleep, circadian rhythms, and human disorders Pre-clinical human investigations, including the measurement and manipulation of sleep and circadian rhythms Studies in clinical or population samples. These may address factors influencing sleep and circadian rhythms (e.g., development and aging, and social and environmental influences) and relationships between sleep, circadian rhythms, health, and disease Clinical trials, epidemiology studies, implementation, and dissemination research.